

Eduardo L Franco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4506958/publications.pdf>

Version: 2024-02-01

435
papers

24,686
citations

8159

76
h-index

9553

142
g-index

457
all docs

457
docs citations

457
times ranked

16695
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of a Carrageenan Gel in Increasing Clearance of Anal Human Papillomavirus Infections in Men: Interim Analysis of a Double-Blind, Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2023, 227, 402-406.	1.9	1
2	Vaginal Microbiome Components as Correlates of Cervical Human Papillomavirus Infection. <i>Journal of Infectious Diseases</i> , 2022, 226, 1084-1097.	1.9	7
3	Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. <i>Clinical Infectious Diseases</i> , 2022, 75, 365-371.	2.9	9
4	Predicted long-term impact of COVID-19 pandemic-related care delays on cancer mortality in Canada. <i>International Journal of Cancer</i> , 2022, 150, 1244-1254.	2.3	69
5	Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples. <i>Journal of Medical Virology</i> , 2022, 94, 2824-2832.	2.5	5
6	Clinical performance of the BD Onclarity extended genotyping assay for the management of women positive for human papillomavirus in cervical cancer screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , cebp.1082.2021.	1.1	4
7	Protection to Self and to One's Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study. <i>Sexually Transmitted Diseases</i> , 2022, 49, 414-422.	0.8	1
8	Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis. <i>Vaccine</i> , 2022, , .	1.7	2
9	Role of Human Leukocyte Antigen Allele Sharing in Human Papillomavirus Infection Transmission Among Heterosexual Couples: Findings From the Hitch Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	0
10	Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level. <i>International Journal of Cancer</i> , 2022, 150, 1422-1430.	2.3	4
11	Male Circumcision and Genital Human Papillomavirus (HPV) Infection in Males and Their Female Sexual Partners: Findings From the HPV Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 1184-1194.	1.9	2
12	A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 919-931.	1.1	3
13	Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial. <i>International Journal of Cancer</i> , 2022, 151, 897-905.	2.3	5
14	Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results. <i>Current Oncology</i> , 2022, 29, 3860-3869.	0.9	3
15	Invited Commentary: Rethinking Cervical Cancer Elimination in Terms of Lifetime Risk Rather Than Arbitrarily Defined Age-Standardized Incidence Rates. <i>American Journal of Epidemiology</i> , 2021, 190, 515-518.	1.6	3
16	Dual staining for p16/Ki67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study. <i>International Journal of Cancer</i> , 2021, 148, 492-501.	2.3	11
17	Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 22-29.	1.1	14
18	Sex- and Type-specific Genital Human Papillomavirus Transmission Rates Between Heterosexual Partners: A Bayesian Reanalysis of the HITCH Cohort. <i>Epidemiology</i> , 2021, 32, 368-377.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Evolution of Public Health Human Papillomavirus Immunization Programs in Canada. <i>Current Oncology</i> , 2021, 28, 991-1007.	0.9	13
20	Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2021, 148, 2859-2860.	2.3	0
21	A Review of Canadian Cancer-Related Clinical Practice Guidelines and Resources during the COVID-19 Pandemic. <i>Current Oncology</i> , 2021, 28, 1020-1033.	0.9	17
22	Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. <i>Cancer Medicine</i> , 2021, 10, 2996-3003.	1.3	9
23	Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. <i>Lancet Public Health</i> , The, 2021, 6, e510-e521.	4.7	39
24	Assessment of the possible inhibitory effect of carrageenan in human papillomavirus DNA testing by polymerase chain reaction amplification. <i>Journal of Medical Virology</i> , 2021, 93, 6408-6411.	2.5	4
25	Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18. <i>Journal of General Virology</i> , 2021, 102, .	1.3	1
26	Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 511.e1-511.e7.	0.7	5
27	Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2021-055009.	0.8	2
28	Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination. <i>JAMA Network Open</i> , 2021, 4, e2115321.	2.8	11
29	Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report. <i>BMC Proceedings</i> , 2021, 15, 16.	1.8	9
30	Reply to Feng et al. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	0
31	Timeliness of diagnosis and treatment: the challenge of childhood cancers. <i>British Journal of Cancer</i> , 2021, 125, 1612-1620.	2.9	10
32	Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2167-2175.	1.1	3
33	Lessons from an unparalleled disruption to cancer prevention and control. <i>Preventive Medicine</i> , 2021, 151, 106686.	1.6	0
34	The noblest among noble public health goals: Preventing suicide. <i>Preventive Medicine</i> , 2021, 152, 106771.	1.6	0
35	Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106560.	0.8	3
36	Carrageenan as a Preventive Agent Against Human Papillomavirus Infection: A Narrative Review. <i>Sexually Transmitted Diseases</i> , 2021, 48, 458-465.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. <i>BMJ Open</i> , 2021, 11, e052084.	0.8	6
38	Association of serum 25-hydroxyvitamin D with prevalence, incidence, and clearance of vaginal HPV infection in young women. <i>Journal of Infectious Diseases</i> , 2021, 224, 492-502.	1.9	4
39	Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per protocol eligible for routine screening. <i>International Journal of Cancer</i> , 2020, 146, 1810-1818.	2.3	0
40	Latency of tobacco smoking for head and neck cancer among HPV-positive and HPV-negative individuals. <i>International Journal of Cancer</i> , 2020, 147, 56-64.	2.3	11
41	Proving the Causal Role of Human Papillomavirus in Cervical Cancer: A Tale of Multidisciplinary Science. , 2020, , 131-147.		4
42	Characterization of the Vaginal Microbiome in Women of Reproductive Age From 5 Regions in Brazil. <i>Sexually Transmitted Diseases</i> , 2020, 47, 562-569.	0.8	33
43	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers. <i>Cancer Prevention Research</i> , 2020, 13, 829-840.	0.7	6
44	Surgeon and hospital volume outcomes in bariatric surgery: a population-level study. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 674-681.	1.0	13
45	Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples. <i>BMJ Open</i> , 2020, 10, e039383.	0.8	6
46	Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2020, 147, 2695-2707.	2.3	14
47	Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035113.	0.8	5
48	Directionality of Genital Human Papillomavirus Infection Transmission Within Heterosexual Couples: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, 1928-1937.	1.9	9
49	Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report. <i>BMC Proceedings</i> , 2020, 14, 8.	1.8	16
50	Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening. <i>International Journal of Cancer</i> , 2020, 147, 3305-3312.	2.3	12
51	Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia. <i>International Journal of Cancer</i> , 2020, 147, 1264-1274.	2.3	15
52	Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1436-1446.	1.1	1
53	Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens. <i>Journal of Medical Microbiology</i> , 2020, 69, 960-970.	0.7	0
54	Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age. <i>Gynecologic Oncology</i> , 2019, 155, 245-253.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. <i>Vaccine</i> , 2019, 37, 6832-6841.	1.7	6
56	Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. <i>Pediatrics</i> , 2019, 143, .	1.0	45
57	Limitations of simulation models for cervical cancer screening – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e69.	5.1	0
58	The burden of cancer attributable to modifiable risk factors in Canada: Methods overview. <i>Preventive Medicine</i> , 2019, 122, 3-8.	1.6	14
59	Human Papillomavirus Viral Load and Transmission in Young, Recently Formed Heterosexual Couples. <i>Journal of Infectious Diseases</i> , 2019, 220, 1152-1161.	1.9	10
60	Cancers attributable to infections in Canada. <i>Preventive Medicine</i> , 2019, 122, 109-117.	1.6	9
61	Estimates of the future burden of cancer attributable to infections in Canada. <i>Preventive Medicine</i> , 2019, 122, 118-127.	1.6	3
62	Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1134-1140.	1.1	23
63	Lack of Association between Human Papillomavirus Types 6 and 11 Genetic Variants and Cervical Abnormalities: The Ludwig-McGill Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1086-1088.	1.1	1
64	The future burden of cancer in Canada: Long-term cancer incidence projections 2013-2042. <i>Cancer Epidemiology</i> , 2019, 59, 199-207.	0.8	40
65	Improving the reporting of cancer-specific mortality and survival in research using cancer registry data. <i>Cancer Epidemiology</i> , 2019, 59, 232-235.	0.8	8
66	Genetic variants in CYP and GST genes, smoking and risk for head and neck cancers: a gene-environment interaction hospital-based case-control study among Canadian Caucasians. <i>Carcinogenesis</i> , 2019, , .	1.3	2
67	Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 317-326.	4.6	14
68	Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1825-1834.	1.1	13
69	Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. <i>JAMA Network Open</i> , 2019, 2, e1915781.	2.8	40
70	Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. <i>Sexually Transmitted Diseases</i> , 2019, 46, 663-669.	0.8	10
71	Restoring Dignity in Academic Publishing Is a Collective Duty. <i>JDR Clinical and Translational Research</i> , 2019, 4, 5-8.	1.1	2
72	Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study. <i>Head and Neck</i> , 2019, 41, 678-685.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. <i>International Journal of Cancer</i> , 2019, 144, 2408-2418.	2.3	1
74	Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1962-1969.	1.4	27
75	Predictors of dysplastic and neoplastic progression of Barrett's esophagus. <i>Canadian Journal of Surgery</i> , 2019, 62, 93-99.	0.5	7
76	Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals. <i>JMIR Research Protocols</i> , 2019, 8, e11284.	0.5	27
77	Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. <i>Gynecologic Oncology</i> , 2018, 149, 491-497.	0.6	14
78	Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. <i>Expert Review of Vaccines</i> , 2018, 17, 395-409.	2.0	19
79	Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection. <i>Sexually Transmitted Diseases</i> , 2018, 45, 260-265.	0.8	26
80	Y Chromosome DNA in Women's Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study. <i>Sexually Transmitted Diseases</i> , 2018, 45, 28-34.	0.8	7
81	Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada. <i>International Journal of Circumpolar Health</i> , 2018, 77, 1556556.	0.5	2
82	Validation of a New HPV Self-Sampling Device for Cervical Cancer Screening: The Cervical and Self-Sample in Screening (CASSIS) Study. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 461-462.	0.2	0
83	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 632-634.	0.2	2
84	Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARE) study. <i>BMJ Open</i> , 2018, 8, e022378.	0.8	29
85	Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study. <i>Lancet Oncology</i> , The, 2018, 19, 1569-1578.	5.1	39
86	Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. <i>Journal of Clinical Virology</i> , 2018, 108, 32-37.	1.6	20
87	Self-Sampling for Cervical Cancer Screening: Empowering Women to Lead a Paradigm Change in Cancer Control. <i>Current Oncology</i> , 2018, 25, 1-3.	0.9	18
88	Prevention of cervical cancer in Latin America: Future challenges and opportunities. <i>Salud Publica De Mexico</i> , 2018, 60, 609.	0.1	2
89	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 43.	3.8	190
90	Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction. <i>Journal of Adolescent Health</i> , 2018, 63, 43-49.	1.2	10

#	ARTICLE	IF	CITATIONS
91	HLA and KIR Associations of Cervical Neoplasia. <i>Journal of Infectious Diseases</i> , 2018, 218, 2006-2015.	1.9	22
92	Journal editors as curators of scholarship: A case study in repairing the scientific record. <i>Preventive Medicine</i> , 2018, 110, 114-115.	1.6	2
93	Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study. <i>Salud Publica De Mexico</i> , 2018, 60, 722.	0.1	7
94	Human Papillomavirus Vaccination: Making Sense of the Public Controversy. , 2018, , 59-94.		0
95	Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 923-929.	1.1	21
96	Aptima HPV Assay versus Hybrid Capture [®] 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. <i>Journal of Clinical Virology</i> , 2017, 87, 23-29.	1.6	33
97	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. <i>Preventive Medicine</i> , 2017, 98, 5-14.	1.6	87
98	Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study. <i>Oral Oncology</i> , 2017, 69, 56-61.	0.8	24
99	Population health intervention research: A renewed commitment to promoting a science of solutions. <i>Preventive Medicine</i> , 2017, 100, 1-2.	1.6	2
100	Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1312-1320.	1.1	11
101	Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. <i>Preventive Medicine</i> , 2017, 98, 15-20.	1.6	34
102	Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?. <i>Cancer</i> , 2017, 123, 1545-1554.	2.0	39
103	Mobile Screening Units for the Early Detection of Cancer: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1679-1694.	1.1	44
104	Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. <i>Carcinogenesis</i> , 2017, 38, 1188-1195.	1.3	53
105	Optimizing secondary prevention of cervical cancer: Recent advances and future challenges. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 15-19.	1.0	39
106	Independent Scientists Provide Guidance for the Future of Cervical Cancer Screening. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 326-327.	0.3	1
107	The Downside of the Shifting Paradigm of Scholarly Publishing in the Biomedical Sciences: Predatory Publishing. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 513-515.	0.3	6
108	Assortativity and Mixing by Sexual Behaviors and Sociodemographic Characteristics in Young Adult Heterosexual Dating Partnerships. <i>Sexually Transmitted Diseases</i> , 2017, 44, 329-337.	0.8	6

#	ARTICLE	IF	CITATIONS
109	HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. <i>International Journal of Cancer</i> , 2017, 140, 440-448.	2.3	70
110	Estimating HPV DNA Deposition Between Sexual Partners Using HPV Concordance, Y Chromosome DNA Detection, and Self-reported Sexual Behaviors. <i>Journal of Infectious Diseases</i> , 2017, 216, 1210-1218.	1.9	25
111	Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study. <i>PLoS Genetics</i> , 2017, 13, e1006866.	1.5	105
112	Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) Performed by Nurse and Physician. <i>PLoS ONE</i> , 2017, 12, e0170631.	1.1	24
113	A collaboration between cousins: The Canadian Journal of Public Health and the Canadian Society for Epidemiology and Biostatistics. <i>Canadian Journal of Public Health</i> , 2016, 107, e1-e2.	1.1	0
114	Periodontal diseases and risk of oral cancer in Southern India: Results from the HeNCE Life study. <i>International Journal of Cancer</i> , 2016, 139, 1512-1519.	2.3	76
115	No role for human papillomavirus infection in oral cancers in a region in southern India. <i>International Journal of Cancer</i> , 2016, 138, 912-917.	2.3	44
116	Assessment of mediators of racial disparities in cervical cancer survival in the United States. <i>International Journal of Cancer</i> , 2016, 138, 2622-2630.	2.3	29
117	Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women. <i>Journal of Women's Health</i> , 2016, 25, 1153-1158.	1.5	2
118	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. <i>BMJ Open</i> , 2016, 6, e011371.	0.8	34
119	Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico. <i>BMC Infectious Diseases</i> , 2016, 16, 461.	1.3	15
120	Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. <i>Clinical Infectious Diseases</i> , 2016, 63, 1281-1287.	2.9	44
121	Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. <i>International Journal of Cancer</i> , 2016, 139, 2456-2466.	2.3	54
122	Nonlinear association between betel quid chewing and oral cancer: Implications for prevention. <i>Oral Oncology</i> , 2016, 60, 25-31.	0.8	26
123	Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 723-726.	0.3	6
124	Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. <i>British Journal of Cancer</i> , 2016, 115, 1487-1494.	2.9	10
125	Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. <i>BMC Public Health</i> , 2016, 16, 213.	1.2	36
126	Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections. <i>Journal of Infectious Diseases</i> , 2016, 214, 676-684.	1.9	9

#	ARTICLE	IF	CITATIONS
127	Should we lower the age for routine HPV vaccination in the United States?. Preventive Medicine, 2016, 89, 334-336.	1.6	0
128	Reproductive and genital health and risk of cervical human papillomavirus infection: results from the Ludwig-McGill cohort study. BMC Infectious Diseases, 2016, 16, 116.	1.3	17
129	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. International Journal of Gynecology and Obstetrics, 2016, 132, 252-258.	1.0	134
130	Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. Journal of Clinical Virology, 2016, 76, S62-S68.	1.6	72
131	Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. PLoS ONE, 2016, 11, e0166329.	1.1	17
132	Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica De Mexico, 2016, 58, 197-210.	0.1	26
133	Human papillomavirus variants among Inuit women in northern Quebec, Canada. International Journal of Circumpolar Health, 2015, 74, 29482.	0.5	5
134	HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status. Cancer Cytopathology, 2015, 123, 745-754.	1.4	37
135	Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer, 2015, 15, 968.	1.1	38
136	Incidence, Persistence, and Determinants of Human Papillomavirus Infection in a Population of Inuit Women in Northern Quebec. Sexually Transmitted Diseases, 2015, 42, 272-278.	0.8	15
137	Perfect is the Enemy of Good: Going to the War on Cancer with Less Evidence than We Could Have. Epidemiologic Methods, 2015, 4, .	0.8	2
138	Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy. BMC Pregnancy and Childbirth, 2015, 15, 244.	0.9	12
139	Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 412-420.	0.3	11
140	Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study. BJU International, 2015, 115, 389-396.	1.3	17
141	Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial. Gynecologic Oncology, 2015, 137, 47-54.	0.6	121
142	Sobering realizations in cancer prevention and screening and their lessons. Preventive Medicine, 2015, 76, 129-131.	1.6	1
143	An elusive low-hanging fruit for public health: Gun violence prevention. Preventive Medicine, 2015, 79, 1-2.	1.6	8
144	Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. International Journal of Cancer, 2015, 136, E638-45.	2.3	51

#	ARTICLE	IF	CITATIONS
145	Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 286-290.	1.1	24
146	Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. <i>Expert Review of Vaccines</i> , 2015, 14, 119-133.	2.0	11
147	What makes an eLife paper in epidemiology and global health?. <i>ELife</i> , 2015, 4, .	2.8	0
148	Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. <i>BMC Public Health</i> , 2014, 14, 1060.	1.2	12
149	Determinants of Human Papillomavirus Coinfections among Montreal University Students: The Influence of Behavioral and Biologic Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 812-822.	1.1	15
150	Making Prospective Registration of Observational Research a Reality. <i>Science Translational Medicine</i> , 2014, 6, 224cm1.	5.8	99
151	Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 578.	1.3	6
152	cobas [®] 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 5-16.	1.5	21
153	Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios. <i>Lung</i> , 2014, 192, 55-63.	1.4	36
154	Sexual Transmission of Oral Human Papillomavirus Infection among Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2959-2964.	1.1	36
155	Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. <i>Vaccine</i> , 2014, 32, 5845-5853.	1.7	49
156	Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. <i>International Journal of Cancer</i> , 2014, 134, 2264-2268.	2.3	72
157	Is there a need for a new journal devoted to preventive medicine?. <i>Preventive Medicine Reports</i> , 2014, 1, 1-2.	0.8	5
158	Determinants of Prevalent Human Papillomavirus in Recently Formed Heterosexual Partnerships: A Dyadic-Level Analysis. <i>Journal of Infectious Diseases</i> , 2014, 210, 846-852.	1.9	21
159	Embracing a new era in cervical cancer screening. <i>Lancet</i> , The, 2014, 383, 493-494.	6.3	15
160	Global Genomic Diversity of Human Papillomavirus 6 Based on 724 Isolates and 190 Complete Genome Sequences. <i>Journal of Virology</i> , 2014, 88, 7307-7316.	1.5	33
161	Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. <i>Vaccine</i> , 2013, 31, 3863-3871.	1.7	43
162	Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada. <i>BMC Public Health</i> , 2013, 13, 438.	1.2	14

#	ARTICLE	IF	CITATIONS
163	Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions. <i>Journal of Clinical Virology</i> , 2013, 58, 660-665.	1.6	3
164	Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. <i>International Journal of Cancer</i> , 2013, 133, 2934-2943.	2.3	43
165	The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. <i>Human Immunology</i> , 2013, 74, 1610-1615.	1.2	29
166	Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. <i>International Journal of Cancer</i> , 2013, 133, 1271-1285.	2.3	171
167	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, 11-31.	1.7	261
168	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	1.7	272
169	Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. <i>Journal of General Virology</i> , 2013, 94, 1858-1864.	1.3	20
170	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, F1-F31.	1.7	40
171	Preventive Medicine: New Editorial Office but the Same Vision. <i>Preventive Medicine</i> , 2013, 56, 1-2.	1.6	4
172	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, G1-G31.	1.7	33
173	Combatting obesity "A helping hand from the business community. <i>Preventive Medicine</i> , 2013, 57, 251-252.	1.6	0
174	77 PREOPERATIVE DELAYS PRIOR TO RADICAL CYSTECTOMY IN PATIENTS WITH BLADDER CANCER: A POPULATION-BASED STUDY. <i>Journal of Urology</i> , 2013, 189, .	0.2	1
175	Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. <i>Journal of General Virology</i> , 2013, 94, 1850-1857.	1.3	30
176	Vaccination and Screening in Cervical Cancer Control and Prevention. , 2013, , 1175-1189.		0
177	Polymorphisms in Genes Involved in Folate Metabolism Modify the Association of Dietary and Circulating Folate and Vitamin B-6 with Cervical Neoplasia. <i>Journal of Nutrition</i> , 2013, 143, 2007-2014.	1.3	16
178	Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination. <i>American Journal of Epidemiology</i> , 2013, 178, 625-634.	1.6	87
179	Counterpoint: Cervical Cancer Screening Guidelines--Approaching the Golden Age. <i>American Journal of Epidemiology</i> , 2013, 178, 1023-1026.	1.6	15
180	Response. <i>Journal of the National Cancer Institute</i> , 2013, 105, 664-665.	3.0	1

#	ARTICLE	IF	CITATIONS
181	Cervical human papillomavirus detection is not affected by menstrual phase. <i>Sexually Transmitted Infections</i> , 2013, 89, 202-206.	0.8	4
182	Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix. <i>International Journal of Cancer</i> , 2013, 132, 1821-1830.	2.3	15
183	Influence of Postoperative Infectious Complications on Long-Term Survival of Lung Cancer Patients: A Population-Based Cohort Study. <i>Journal of Thoracic Oncology</i> , 2013, 8, 554-561.	0.5	116
184	The frequency of HLA alleles in a population of Inuit women of northern Quebec. <i>International Journal of Circumpolar Health</i> , 2013, 72, 21350.	0.5	6
185	Accuracy of p53 Codon 72 Polymorphism Status Determined by Multiple Laboratory Methods: A Latent Class Model Analysis. <i>PLoS ONE</i> , 2013, 8, e56430.	1.1	10
186	Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?. <i>PLoS ONE</i> , 2013, 8, e67072.	1.1	5
187	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. <i>American Journal of Clinical Pathology</i> , 2012, 137, 516-542.	0.4	686
188	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 175-204.	0.9	310
189	Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1240-1244.	1.8	24
190	Burden of disease, health indicators and challenges for epidemiology in North America. <i>International Journal of Epidemiology</i> , 2012, 41, 540-556.	0.9	8
191	Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. <i>Journal of Medical Screening</i> , 2012, 19, 42-48.	1.1	254
192	Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. <i>Sexual Health</i> , 2012, 9, 547.	0.4	24
193	Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery. <i>Obstetrics and Gynecology</i> , 2012, 119, 717-724.	1.2	112
194	Inuit women's attitudes and experiences towards cervical cancer and prevention strategies in Nunavik, Quebec. <i>International Journal of Circumpolar Health</i> , 2012, 71, 17996.	0.5	23
195	Towards more eclectic evidence-based medicine in cancer prevention and control. <i>Preventive Medicine</i> , 2012, 55, 552-553.	1.6	3
196	Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus. <i>Virology Journal</i> , 2012, 9, 243.	1.4	0
197	Circulating Biomarkers of Iron Storage and Clearance of Incident Human Papillomavirus Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 859-865.	1.1	18
198	Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy. <i>Vaccine</i> , 2012, 30, F175-F182.	1.7	35

#	ARTICLE	IF	CITATIONS
199	Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 781-789.	4.6	343
200	Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model-Based Analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1712-1723.	3.0	119
201	The psychosocial impact of an abnormal cervical smear result. <i>Psycho-Oncology</i> , 2012, 21, 1071-1081.	1.0	80
202	Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: Markers of immune response?. <i>International Journal of Cancer</i> , 2012, 131, 219-228.	2.3	4
203	Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix. <i>International Journal of Cancer</i> , 2012, 131, E312-9.	2.3	64
204	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 147-172.	157.7	1,022
205	Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo. <i>Gynecologic Oncology</i> , 2012, 124, 286-291.	0.6	18
206	Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction. <i>PLoS ONE</i> , 2012, 7, e39236.	1.1	11
207	Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. <i>Human Immunology</i> , 2011, 72, 337-341.	1.2	50
208	Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Women From a Sub-Saharan African Community. <i>Sexually Transmitted Diseases</i> , 2011, 38, 308-315.	0.8	19
209	Meeting Report: National Symposium on Infectious Agents and Cancer. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, e16-e16.	0.7	0
210	The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study. <i>Sexually Transmitted Diseases</i> , 2011, 38, 949-956.	0.8	68
211	Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. <i>Preventive Medicine</i> , 2011, 53, S12-S21.	1.6	201
212	Awareness and Knowledge about Human Papillomavirus Among Inuit Women in Nunavik, Quebec. <i>Journal of Community Health</i> , 2011, 36, 56-62.	1.9	9
213	Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. <i>Journal of Medical Virology</i> , 2011, 83, 1034-1041.	2.5	61
214	Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. <i>International Journal of Cancer</i> , 2011, 129, 671-679.	2.3	20
215	Associations of dietary dark-green and deep-yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking. <i>British Journal of Nutrition</i> , 2011, 105, 928-937.	1.2	23
216	Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. <i>Journal of Infectious Diseases</i> , 2011, 204, 372-376.	1.9	110

#	ARTICLE	IF	CITATIONS
217	HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIV. <i>Clinical Infectious Diseases</i> , 2011, 52, 1174-1181.	2.9	143
218	Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix. <i>Journal of Clinical Microbiology</i> , 2011, 49, 48-53.	1.8	18
219	Loss of quality of life associated with genital warts: baseline analyses from a prospective study. <i>Sexually Transmitted Infections</i> , 2011, 87, 209-215.	0.8	22
220	Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples. <i>Journal of Infectious Diseases</i> , 2011, 204, 1723-1729.	1.9	80
221	Optimizing technology for cervical cancer screening in high-resource settings. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 343-353.	0.4	18
222	Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study. <i>PLoS ONE</i> , 2011, 6, e16412.	1.1	47
223	Influence of Partner's Infection Status on Prevalent Human Papillomavirus Among Persons With a New Sex Partner. <i>Sexually Transmitted Diseases</i> , 2010, 37, 34-40.	0.8	39
224	Human Papillomavirus Infections Among Couples in New Sexual Relationships. <i>Epidemiology</i> , 2010, 21, 31-37.	1.2	74
225	A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). <i>BMC Cancer</i> , 2010, 10, 111.	1.1	68
226	Are endometrial polyps true cancer precursors?. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 232.e1-232.e6.	0.7	23
227	What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?. <i>Gynecologic Oncology</i> , 2010, 117, 481-485.	0.6	16
228	Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 2010, 118, 289-294.	0.6	39
229	Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada. <i>International Journal of Cancer</i> , 2010, 126, 1936-1943.	2.3	34
230	Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis. <i>International Journal of Cancer</i> , 2010, 127, 1680-1691.	2.3	95
231	Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. <i>Journal of Medical Virology</i> , 2010, 82, 1168-1178.	2.5	17
232	Validation of dot blot hybridization and denaturing high performance liquid chromatography as reliable methods for TP53 codon 72 genotyping in molecular epidemiologic studies. <i>BMC Genetics</i> , 2010, 11, 44.	2.7	4
233	Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. <i>BMC Infectious Diseases</i> , 2010, 10, 326.	1.3	45
234	Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity. <i>Cancer Research</i> , 2010, 70, 8569-8577.	0.4	122

#	ARTICLE	IF	CITATIONS
235	The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: A randomised controlled study. <i>Psychology and Health</i> , 2010, 25, 651-668.	1.2	31
236	No Association between Endogenous Retinoic Acid and Human Papillomavirus Clearance or Incident Cervical Lesions in Brazilian Women. <i>Cancer Prevention Research</i> , 2010, 3, 1007-1014.	0.7	7
237	Invited Commentary: Human Papillomavirus Infection and Risk of Cervical Precancer--Using the Right Methods to Answer the Right Questions. <i>American Journal of Epidemiology</i> , 2010, 171, 164-168.	1.6	7
238	Use of the Normalized Absorbance Ratio as an Internal Standardization Approach To Minimize Measurement Error in Enzyme-Linked Immunosorbent Assays for Diagnosis of Human Papillomavirus Infection. <i>Journal of Clinical Microbiology</i> , 2010, 48, 791-796.	1.8	20
239	Radiodiagnostic Imaging in Pregnancy and the Risk of Childhood Malignancy: Raising the Bar. <i>PLoS Medicine</i> , 2010, 7, e1000338.	3.9	3
240	Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. <i>Sexual Health</i> , 2010, 7, 376.	0.4	29
241	Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control. <i>Future Oncology</i> , 2010, 6, 1725-1733.	1.1	7
242	Persistent HPV Infection and Cervical Cancer Risk: Is the Scientific Rationale for Changing the Screening Paradigm Enough?. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1451-1453.	3.0	5
243	Determinants of Human Papillomavirus Infection Among Inuit Women of Northern Quebec, Canada. <i>Sexually Transmitted Diseases</i> , 2010, 37, 377-381.	0.8	18
244	Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men. <i>Aids</i> , 2010, 24, 2355-2363.	1.0	22
245	How Multidisciplinary Research Advanced the Mission of Cervical Cancer Prevention. <i>Public Health Genomics</i> , 2009, 12, 264-267.	0.6	0
246	Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV-Infected Men: The HIPVIRG Cohort Study. <i>Journal of Infectious Diseases</i> , 2009, 199, 965-973.	1.9	176
247	Bernard Duval: The Architect of Quebec's HPV Immunization Programme. <i>Public Health Genomics</i> , 2009, 12, 261-263.	0.6	1
248	Integrating Human Papillomavirus Vaccination in Cervical Cancer Control Programmes. <i>Public Health Genomics</i> , 2009, 12, 352-361.	0.6	16
249	Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 854-862.	1.1	45
250	Epidemiology's Contributions to a Nobel Prize Recognition. <i>Epidemiology</i> , 2009, 20, 632-634.	1.2	6
251	Effectiveness of Cervical Cancer Screening at Different Ages. <i>Women's Health</i> , 2009, 5, 613-616.	0.7	4
252	Managing low grade and borderline cervical abnormalities. <i>BMJ: British Medical Journal</i> , 2009, 339, b3014-b3014.	2.4	1

#	ARTICLE	IF	CITATIONS
253	A New Generation of Studies of Human Papillomavirus DNA Testing in Cervical Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1600-1601.	3.0	15
254	Brief Research Report: Uncertainty-Inducing and Reassuring Facts About HPV: A Descriptive Study of French Canadian Women. <i>Health Care for Women International</i> , 2009, 30, 892-902.	0.6	3
255	Prognostic Value of Measuring Load of Human Papillomavirus DNA in Cervical Samples: An Elusive Target. <i>Journal of the National Cancer Institute</i> , 2009, 101, 131-133.	3.0	8
256	Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. <i>BMC Medicine</i> , 2009, 7, 69.	2.3	23
257	The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change. <i>Archives of Medical Research</i> , 2009, 40, 478-485.	1.5	104
258	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. <i>International Journal of Cancer</i> , 2009, 124, 516-520.	2.3	557
259	Detection and Typing of Human Papillomavirus Nucleic Acids in Biological Fluids. <i>Public Health Genomics</i> , 2009, 12, 308-318.	0.6	17
260	Low-risk human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous intraepithelial lesions. <i>Journal of Clinical Virology</i> , 2009, 45, 96-99.	1.6	7
261	Is the UK ready to embrace HPV testing?. <i>Lancet Oncology</i> , The, 2009, 10, 643-644.	5.1	3
262	Infectious Diseases and Cancer: HPV. <i>Statistics in the Health Sciences</i> , 2009, , 409-429.	0.2	0
263	Newly isolated HPV97, related to HPV18 and 45 is frequently detected in HIV positive men from the montreal area. <i>International Journal of Cancer</i> , 2008, 122, 1195-1197.	2.3	4
264	Use of latent class models to accommodate inter-laboratory variation in assessing genetic polymorphisms associated with disease risk. <i>BMC Genetics</i> , 2008, 9, 51.	2.7	6
265	Delays in diagnosis and treatment among children and adolescents with cancer in Canada. <i>Pediatric Blood and Cancer</i> , 2008, 51, 468-474.	0.8	91
266	Selected class I and class II HLA alleles and haplotypes and risk of high grade cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2008, 122, 2820-2826.	2.3	33
267	Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer. <i>BMC Cancer</i> , 2008, 8, 246.	1.1	30
268	Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. <i>Oral Oncology</i> , 2008, 44, 242-250.	0.8	113
269	Cervical cancer screening following prophylactic human papillomavirus vaccination. <i>Vaccine</i> , 2008, 26, A16-A23.	1.7	103
270	Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. <i>Vaccine</i> , 2008, 26, F46-F58.	1.7	48

#	ARTICLE	IF	CITATIONS
271	Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L88-L95.	1.7	40
272	Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. <i>Vaccine</i> , 2008, 26, L96-L107.	1.7	44
273	Cost-effectiveness analysis: An essential tool to inform public health policy in cervical cancer prevention. <i>Vaccine</i> , 2008, 26, F1-F2.	1.7	3
274	Ovarian cancer and oral contraceptives. <i>Lancet</i> , The, 2008, 371, 277-278.	6.3	6
275	Genotyping of Human Papillomavirus DNA in Anal Biopsies and Anal Swabs Collected From HIV-Seropositive Men With Anal Dysplasia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 32-39.	0.9	39
276	Human papillomavirus vaccination and screening as the new paradigm in cervical cancer prevention. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 261-263.	0.2	1
277	Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in Nunavik, Quebec. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3141-3149.	1.1	38
278	Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia. <i>Journal of General Virology</i> , 2008, 89, 1716-1728.	1.3	16
279	Type-specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and Vaccination. <i>Journal of Infectious Diseases</i> , 2008, 197, 1436-1447.	1.9	151
280	Reassessing the Epidemiology of Human Papillomavirus Infection: Back to Basics. <i>Sexually Transmitted Diseases</i> , 2008, 35, 283-285.	0.8	0
281	Re: Human Papillomavirus Type 16 and 18 Variants: Race-Related Distribution and Persistence. <i>Journal of the National Cancer Institute</i> , 2007, 99, 653-654.	3.0	9
282	Prophylactic human papillomavirus vaccines: potential for sea change. <i>Expert Review of Vaccines</i> , 2007, 6, 511-525.	2.0	8
283	Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 716-722.	1.1	24
284	Koilocytosis in Oral Squamous Cell Carcinoma: What Does It Mean?. <i>The Journal of Otolaryngology</i> , 2007, 36, 26.	0.6	8
285	Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted. <i>BMJ: British Medical Journal</i> , 2007, 335, 378-379.	2.4	11
286	Vaccination against human papillomavirus. <i>Cmaj</i> , 2007, 177, 1524-1525.	0.9	4
287	Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. <i>Future Oncology</i> , 2007, 3, 319-327.	1.1	18
288	A New Window into the Natural History of Human Papillomavirus Infection: A View from the ALTS (Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions) Tj ETQq0 0 0rgBT /Overlock 10		

#	ARTICLE	IF	CITATIONS
289	Multiparameter Calibration of a Natural History Model of Cervical Cancer. <i>American Journal of Epidemiology</i> , 2007, 166, 137-150.	1.6	131
290	Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3821-3823.	1.8	42
291	HLA Polymorphisms and Cervical Human Papillomavirus Infection in a Cohort of Montreal University Students. <i>Journal of Infectious Diseases</i> , 2007, 196, 82-90.	1.9	36
292	Polymorphism of the L1 Capsid Gene and Persistence of Human Papillomavirus Type 52 Infection in Women at High Risk or Infected by HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 61-65.	0.9	12
293	BROGLY ET AL. RESPOND. <i>American Journal of Public Health</i> , 2007, 97, 1930-1930.	1.5	0
294	Reproductive Health of Adolescent Girls Perinatally Infected With HIV. <i>American Journal of Public Health</i> , 2007, 97, 1047-1052.	1.5	104
295	Cost-effectiveness of HPV 16, 18 vaccination in Brazil. <i>Vaccine</i> , 2007, 25, 6257-6270.	1.7	139
296	Process of care failures in invasive cervical cancer: Systematic review and meta-analysis. <i>Preventive Medicine</i> , 2007, 45, 93-106.	1.6	224
297	Haptoglobin phenotype and risk of cervical neoplasia: A case-control study. <i>Clinica Chimica Acta</i> , 2007, 385, 67-72.	0.5	18
298	Associations between serum carotenoids and tocopherols and type-specific HPV persistence: The Ludwig-McGill cohort study. <i>International Journal of Cancer</i> , 2007, 120, 672-680.	2.3	21
299	Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix. <i>International Journal of Cancer</i> , 2007, 121, 2674-2681.	2.3	14
300	Diagnosis delays in childhood cancer. <i>Cancer</i> , 2007, 110, 703-713.	2.0	198
301	Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2007, 105, 530-535.	0.6	240
302	Response to Pretorius and Belinson. <i>Gynecologic Oncology</i> , 2007, 107, 596-597.	0.6	0
303	Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1579-1588.	13.9	930
304	Epidemiological methods: a view from the Americas. , 2007, , 275-288.		0
305	Is HPV testing with cytological triage a more logical approach in cervical cancer screening?. <i>Lancet Oncology</i> , The, 2006, 7, 527-529.	5.1	9
306	Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. <i>Lancet</i> , The, 2006, 367, 1247-1255.	6.3	1,395

#	ARTICLE	IF	CITATIONS
307	Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. <i>Journal of Clinical Virology</i> , 2006, 36, 133-140.	1.6	23
308	The epidemiology of genital human papillomavirus infection. <i>Vaccine</i> , 2006, 24, S4-S15.	1.7	383
309	Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. <i>Vaccine</i> , 2006, 24, S52-S61.	1.7	364
310	Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. <i>Vaccine</i> , 2006, 24, S171-S177.	1.7	183
311	Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. <i>Vaccine</i> , 2006, 24, S242-S249.	1.7	19
312	Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. <i>Vaccine</i> , 2006, 24, S251-S261.	1.7	44
313	Epidemiology of Oncogenic and Nononcogenic HPV Types, and the Evidence for Differences in Their Sexual Transmissibility. , 2006, , 20-33.		0
314	Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, S65-S81.	1.1	77
315	Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. <i>European Journal of Cancer Prevention</i> , 2006, 15, 158-164.	0.6	49
316	Lack of Agreement Between Cervicography and Cytology and the Effect of Human Papillomavirus Infection and Viral Load. <i>Journal of Lower Genital Tract Disease</i> , 2006, 10, 229-237.	0.9	3
317	Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). <i>International Journal of Cancer</i> , 2006, 119, 615-623.	2.3	93
318	Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. <i>International Journal of Cancer</i> , 2006, 119, 1389-1395.	2.3	94
319	High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. <i>Journal of Medical Virology</i> , 2006, 78, 814-819.	2.5	39
320	Comparison of Psychosocial Outcomes in Head and Neck Cancer Patients Receiving a Coping Strategies Intervention and Control Subjects Receiving No Intervention. <i>The Journal of Otolaryngology</i> , 2006, 35, 88.	0.6	35
321	Human Papillomavirus Type 33 Polymorphisms and High-Grade Squamous Intraepithelial Lesions of the Uterine Cervix. <i>Journal of Infectious Diseases</i> , 2006, 194, 886-894.	1.9	33
322	Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada. <i>American Journal of Epidemiology</i> , 2006, 163, 534-543.	1.6	108
323	Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1274-1280.	1.1	280
324	Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1998-2006.	1.8	157

#	ARTICLE	IF	CITATIONS
325	Cancer Precursors. , 2006, , 21-46.		3
326	Epidemiology As a Tool to Reveal Inequalities in Breast Cancer Care. PLoS Medicine, 2006, 3, e48.	3.9	4
327	Human papillomavirus and cervical cancer: burden of illness and basis for prevention. American Journal of Managed Care, 2006, 12, S462-72.	0.8	34
328	The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detection and Prevention, 2005, 29, 307-316.	2.1	34
329	The Laboratory Diagnosis of Genital Human Papillomavirus Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005, 16, 83-91.	0.7	34
330	Modifiable Risk Factors Associated with Clearance of Type-Specific Cervical Human Papillomavirus Infections in a Cohort of University Students. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1149-1156.	1.1	72
331	Management of low-grade cervical lesions in young women. Cmaj, 2005, 173, 771-774.	0.9	12
332	Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine, 2005, 23, 2388-2394.	1.7	187
333	The Role of Human Papillomaviruses in Cancer. American Journal of Cancer, 2005, 4, 49-64.	0.4	24
334	p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 11-22.	1.1	153
335	Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. Journal of the National Cancer Institute, 2004, 96, 604-615.	3.0	482
336	Male Circumcision and AIDS in Africa. Epidemiology, 2004, 15, 133-134.	1.2	11
337	Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction, 2004, 99, 727-737.	1.7	40
338	Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene, 2004, 23, 6535-6540.	2.6	45
339	Role and limitations of epidemiology in establishing a causal association. Seminars in Cancer Biology, 2004, 14, 413-426.	4.3	25
340	Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecologic Oncology, 2004, 92, 856-865.	0.6	75
341	Cancer of the Uterine Cervix. BMC Women's Health, 2004, 4, S13.	0.8	32
342	Randomized controlled trials of HPV testing and pap cytology: Toward evidence-based cervical cancer prevention. International Journal of Cancer, 2004, 110, 1-2.	2.3	6

#	ARTICLE	IF	CITATIONS
343	Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 809-814.	0.4	48
344	Evaluation of a convenient enzyme immunoassay to assess the quality of genital specimens submitted for the detection of human papillomavirus DNA by consensus PCR. <i>Journal of Clinical Virology</i> , 2004, 29, 127-133.	1.6	5
345	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. <i>Lancet, The</i> , 2004, 364, 1757-1765.	6.3	1,435
346	Electrofulguration for Low-Grade Squamous Intraepithelial Lesions of the Cervix (CIN 1). <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 10-15.	0.9	2
347	Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2004, 26, 1004-1014.	0.3	18
348	An overview of epidemiological and public health research on HPVs presented at the 21st International Papillomavirus Conference in Mexico City, 20-26 February 2004. <i>Papillomavirus Report</i> , 2004, 15, 121-123.	0.2	7
349	Epidemiology of Cervical, Vulvar, and Vaginal Cancers. , 2004, , 3-30.		2
350	Temporal variation and identification of factors associated with endogenous retinoic acid isomers in serum from Brazilian women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1693-703.	1.1	3
351	Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1336-1343.	3.0	269
352	Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 129-134.	0.7	36
353	Toward a reduction of the global burden of cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, S37-S39.	0.7	18
354	Innovations in understanding the biology of cervical cancer. <i>Cancer</i> , 2003, 98, 2064-2069.	2.0	35
355	Viral load as a predictor of the risk of cervical intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2003, 103, 519-524.	2.3	129
356	A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. <i>International Journal of Cancer</i> , 2003, 106, 896-904.	2.3	159
357	Are we ready for a paradigm change in cervical cancer screening?. <i>Lancet, The</i> , 2003, 362, 1866-1867.	6.3	14
358	Towards More Effective Public Health Programming for Injection Drug Users: Development and Evaluation of the Injection Drug User Quality of Life Scale. <i>Substance Use and Misuse</i> , 2003, 38, 965-992.	0.7	45
359	Dietary Intake and Risk of Persistent Human Papillomavirus (HPV) Infection: The Ludwigâ€McGill HPV Natural History Study. <i>Journal of Infectious Diseases</i> , 2003, 188, 1508-1516.	1.9	76
360	Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions. <i>American Journal of Epidemiology</i> , 2003, 158, 878-886.	1.6	17

#	ARTICLE	IF	CITATIONS
361	Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests. Journal of the National Cancer Institute Monographs, 2003, 2003, 89-96.	0.9	119
362	Is Colposcopy Warranted in Women with External Anogenital Warts?. Journal of Lower Genital Tract Disease, 2003, 7, 22-28.	0.9	2
363	The Epidemiology of Cervical Cancer. Cancer Journal (Sudbury, Mass), 2003, 9, 348-359.	1.0	196
364	Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities. Sexually Transmitted Diseases, 2003, 30, 581-587.	0.8	70
365	Prospects for controlling cervical cancer at the turn of the century. Salud Publica De Mexico, 2003, 45, 367-375.	0.1	16
366	The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 485-90.	1.1	129
367	Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1029-37.	1.1	29
368	Use of PGMV Primers in L1 Consensus PCR Improves Detection of Human Papillomavirus DNA in Genital Samples. Journal of Clinical Microbiology, 2002, 40, 902-907.	1.8	152
369	Predictive Factors for Diagnosis of Advanced-Stage Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 2002, 128, 313.	1.5	81
370	Polymorphisms of the Human Leukocyte Antigen DRB1 and DQB1 Genes and the Natural History of Human Papillomavirus Infection. Journal of Infectious Diseases, 2002, 186, 164-172.	1.9	51
371	Cervix. , 2002, , 249-286.		5
372	HIV-Positive Notification and Behavior Changes in Montreal Injection Drug Users. AIDS Education and Prevention, 2002, 14, 17-28.	0.6	15
373	Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncology, The, 2002, 3, 11-16.	5.1	196
374	Past, present, and future of HPV research: highlights from the 19th International Papillomavirus Conference-HPV2001. Virus Research, 2002, 89, 163-173.	1.1	11
375	Evidence-based policy recommendations on cancer screening and prevention. Cancer Detection and Prevention, 2002, 26, 350-361.	2.1	28
376	Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix. Journal of Medical Virology, 2002, 68, 606-610.	2.5	13
377	Assessing the gain in diagnostic performance when combining two diagnostic tests. Statistics in Medicine, 2002, 21, 2527-2546.	0.8	81
378	Assessing Epidemiological Relations and the Role of Measurement Errors. , 2002, , 60-74.		0

#	ARTICLE	IF	CITATIONS
379	Assessment of control selection bias in a hospital-based case-control study of upper aero-digestive tract cancers. <i>Journal of Cancer Epidemiology and Prevention</i> , 2002, 7, 131-41.	1.1	11
380	Cervical-cancer screening beyond the year 2000. <i>Lancet Oncology</i> , The, 2001, 2, 27-32.	5.1	29
381	Oncogenic Human Papillomavirus Infection and Cervical Lesions in Aboriginal Women of Nunavut, Canada. <i>Sexually Transmitted Diseases</i> , 2001, 28, 694-700.	0.8	46
382	Effect of type of alcoholic beverage on the risks of upper aerodigestive tract cancers in Brazil. <i>Cancer Causes and Control</i> , 2001, 12, 579-587.	0.8	43
383	Determinants of Low-Risk and High-Risk Cervical Human Papillomavirus Infections in Montreal University Students. <i>Sexually Transmitted Diseases</i> , 2000, 27, 79-86.	0.8	62
384	Risk behaviour change and HIV infection among injection drug users in Montreal. <i>Aids</i> , 2000, 14, 2575-2582.	1.0	16
385	Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats. <i>Bioelectromagnetics</i> , 2000, 21, 84-93.	0.9	13
386	p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. <i>International Journal of Cancer</i> , 2000, 87, 528-533.	2.3	90
387	Statistical Issues in Human Papillomavirus Testing and Screening. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 345-367.	0.7	25
388	Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. <i>Journal of General Virology</i> , 2000, 81, 2959-2968.	1.3	256
389	Comparison of endocervical curettage and endocervical brushing. <i>Obstetrics and Gynecology</i> , 2000, 96, 90-94.	1.2	18
390	Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats. <i>Bioelectromagnetics</i> , 2000, 21, 84.	0.9	1
391	p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. , 2000, 87, 528.		2
392	Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. <i>Cancer</i> , 1999, 85, 1903-1909.	2.0	67
393	Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 181, 382-386.	0.7	44
394	Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. , 1999, 85, 1903-1909.		53
395	Effect of Smoking Cessation and Tobacco Type on the Risk of Cancers of the Upper Aero-Digestive Tract in Brazil. <i>Epidemiology</i> , 1999, 10, 412-418.	1.2	94
396	Nonisotopic Detection and Typing of Human Papillomavirus DNA in Genital Samples by the Line Blot Assay. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1852-1857.	1.8	50

#	ARTICLE	IF	CITATIONS
397	Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 1999, 6, 223-233.	0.6	80
398	Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. <i>Diagnostic Cytopathology</i> , 1998, 19, 89-93.	0.5	30
399	A prospective epidemiological study of gastrointestinal health effects due to the consumption of drinking water. <i>International Journal of Environmental Health Research</i> , 1997, 7, 5-31.	1.3	211
400	The future of HPV testing in clinical laboratories and applied virology research. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 123-141.	1.8	34
401	Human papillomavirus infection in postmenopausal women with and without hormone therapy. <i>Obstetrics and Gynecology</i> , 1997, 90, 7-11.	1.2	49
402	Evaluation of the potential carcinogenicity of 60 Hz linear sinusoidal continuous-wave magnetic fields in Fischer F344 rats. <i>FASEB Journal</i> , 1997, 11, 1127-1136.	0.2	45
403	Conventional Cervical Cytologic Smears vs. ThinPrep Smears. <i>Acta Cytologica</i> , 1996, 40, 1136-1142.	0.7	63
404	Use of Dipyrone during Pregnancy and Risk of Wilms' Tumor. <i>Epidemiology</i> , 1996, 7, 533-535.	1.2	76
405	Etiology of Wilms' Tumor. <i>Epidemiologic Reviews</i> , 1995, 17, 415-432.	1.3	30
406	Parental Exposures to Pesticides and Risk of Wilms' Tumor in Brazil. <i>American Journal of Epidemiology</i> , 1995, 141, 210-217.	1.6	68
407	Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: A case-control study. <i>International Journal of Cancer</i> , 1995, 63, 769-773.	2.3	98
408	Associations between Cigarette Smoking and Each of 21 Types of Cancer: A Multi-Site Case-Control Study. <i>International Journal of Epidemiology</i> , 1995, 24, 504-514.	0.9	124
409	Factors Influencing Regional Lymph Node Metastasis from Laryngeal Carcinoma. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 1995, 104, 442-447.	0.6	38
410	The effect of cervical loop electrosurgical excision on subsequent pregnancy outcome: North American experience. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 172, 1246-1250.	0.7	66
411	ARE THE APPARENT EFFECTS OF CIGARETTE SMOKING ON LUNG AND BLADDER CANCERS DUE TO UNCONTROLLED CONFOUNDING BY OCCUPATIONAL EXPOSURES?. <i>Epidemiology</i> , 1994, 5, 57-65.	1.2	16
412	A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of wilms' tumor. Results after extended follow-up. <i>Cancer</i> , 1994, 73, 3081-3086.	2.0	20
413	Lateness of diagnosis of oral and oropharyngeal carcinoma: Factors related to the tumour, the patient and health professionals. <i>European Journal of Cancer Part B, Oral Oncology</i> , 1994, 30, 167-173.	0.9	131
414	Incidence of Norwalk virus infections during a prospective epidemiological study of drinking water related gastrointestinal illness. <i>Canadian Journal of Microbiology</i> , 1994, 40, 805-809.	0.8	27

#	ARTICLE	IF	CITATIONS
415	Matã©, Coffee, and Tea Consumption and Risk of Cancers of the Upper Aerodigestive Tract in Southern Brazil. <i>Epidemiology</i> , 1994, 5, 583-590.	1.2	90
416	Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer. <i>International Journal of Cancer</i> , 1993, 53, 707-708.	2.3	15
417	Race and gender influences on the survival of patients with mouth cancer. <i>Journal of Clinical Epidemiology</i> , 1993, 46, 37-46.	2.4	50
418	Absence of Relationship between Health Effects Due to Tap Water Consumption and Drinking Water Quality Parameters. <i>Water Science and Technology</i> , 1993, 27, 137-143.	1.2	33
419	Response Design options for the study of second cancers. <i>Journal of Clinical Epidemiology</i> , 1991, 44, 629-632.	2.4	1
420	Presentation Risk factors for second cancers of the upper respiratory and digestive systems: A case-control study. <i>Journal of Clinical Epidemiology</i> , 1991, 44, 615-625.	2.4	74
421	Multiple cancers of the upper aero-digestive tract: the challenge of risk factor identification. <i>Cancer Letters</i> , 1991, 60, 1-8.	3.2	18
422	Epidemiological and clinical correlations with genetic characteristics of Wilms' tumor: Results of the Brazilian Wilms' tumor study group. <i>International Journal of Cancer</i> , 1991, 48, 641-646.	2.3	9
423	Single-dose versus fractionated-dose dactinomycin in the treatment of wilms' tumor. Preliminary results of a clinical trial. <i>Cancer</i> , 1991, 67, 2990-2996.	2.0	10
424	Prognostic factors in laryngeal cancer patients submitted to surgical treatment. <i>Journal of Surgical Oncology</i> , 1991, 48, 87-95.	0.8	44
425	The Sexually Transmitted Disease Model for Cervical Cancer. <i>Epidemiology</i> , 1991, 2, 98-106.	1.2	80
426	A MICROCOMPUTER PROGRAM FOR MULTIPLE LOGISTIC REGRESSION BY UNCONDITIONAL AND CONDITIONAL MAXIMUM LIKELIHOOD METHODS1. <i>American Journal of Epidemiology</i> , 1989, 129, 439-444.	1.6	123
427	Age and lateness of referral as determinants of extra-ocular retinoblastoma. <i>Ophthalmic Paediatrics and Genetics</i> , 1989, 10, 179-184.	0.4	81
428	Risk factors for oral cancer in Brazil: A case-control study. <i>International Journal of Cancer</i> , 1989, 43, 992-1000.	2.3	337
429	Correlation patterns of cancer relative frequencies with some socioeconomic and demographic indicators in Brazil: An ecologic study. <i>International Journal of Cancer</i> , 1988, 41, 24-29.	2.3	30
430	Plasminogen activator expression and steroid hormone receptors in female breast cancer: A multifactorial study. <i>International Journal of Cancer</i> , 1988, 41, 798-804.	2.3	11
431	An Oocyst-Transmitted Outbreak of Toxoplasmosis: Patterns of Immunoglobulin G and M over One Year. <i>American Journal of Tropical Medicine and Hygiene</i> , 1986, 35, 290-296.	0.6	25
432	Computer-assisted multiple categorization of absorbance values in ELISA through pictorial emulation of 96-well plates. <i>Journal of Immunological Methods</i> , 1984, 70, 45-52.	0.6	6

#	ARTICLE	IF	CITATIONS
433	Diagnosis of Acute Acquired Toxoplasmosis with the Enzyme-Labelled Antigen Reversed Immunoassay for Immunoglobulin M Antibodies. Journal of Immunoassay, 1983, 4, 373-393.	0.3	11
434	The potential harms of personal lubricants. Jornal Brasileiro De DoenÇas Sexualmente TransmissÃveis, 0, 32, .	0.1	0
435	Ecological analysis of correlates of cervical cancer morbidity and mortality in Sub-Saharan Africa. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	1